Joint bleeding episodes and factor replacement usage
. | 6-wk base study . | . | 6-mo extension study . | . | ||
|---|---|---|---|---|---|---|
. | Placebo . | Etoricoxib 90 mg . | Rofecoxib 25 mg . | Etoricoxib 90 mg . | ||
| Joint bleeding episodes, no. of patients (%) | 37 (72.6) | 34 (66.7) | 15 (78.9) | 57 (77.0) | ||
| Factor use for joint bleeding episodes, no. of patients (%) | 35 (68.6) | 33 (64.7) | 15 (78.9) | 56 (75.7) | ||
. | 6-wk base study . | . | 6-mo extension study . | . | ||
|---|---|---|---|---|---|---|
. | Placebo . | Etoricoxib 90 mg . | Rofecoxib 25 mg . | Etoricoxib 90 mg . | ||
| Joint bleeding episodes, no. of patients (%) | 37 (72.6) | 34 (66.7) | 15 (78.9) | 57 (77.0) | ||
| Factor use for joint bleeding episodes, no. of patients (%) | 35 (68.6) | 33 (64.7) | 15 (78.9) | 56 (75.7) | ||